Article Listing - Merck KGaA revenues, core EPS rocket but 4th-qtr operating results slump 21%

EUROPEAN ASTHMA TREATMENT MARKET

6 April 1992

Sales of beta-2 agonists in Europe will grow from $485 million in 1990 to almost $983 million by 1995, or...

LOWER SALES/PROFIT FOR BAYER ITALY

6 April 1992

In line with the group's overall international performance, Bayer Italia reports lower sales and profits in 1991. The subsidiary of...

FUTURE PRODUCTS FROM GENETICS INSTITUTE

6 April 1992

Highlighting the most prominent products and product candidates in its commercial development pipeline, Genetics Institute acknowledges that significant progress has...

ASPIRIN HELPS BAYER IN ITALY

6 April 1992

Favorable trends in drugs business and especially good sales of standard products such as aspirin are reported to have helped...

US HOSPITAL FORMULARY GUIDE

6 April 1992

The American Society of Hospital Pharmacists has released guidelines on formulary system management for its members.

The ASHP notes that in...

new swiss hospital costs program

6 April 1992

The Swiss Federal Council has come out in support of the need for severe measures to combat increasing health care...

ARIAD PHARMACEUTICALS STOCK SALE

6 April 1992

The biotechnology concern Ariad Pharmaceuticals of the USA is reported to have raised $46 million in a private stock sale,...

US MEDICAID REBATES AND "BEST PRICES"

6 April 1992

Eliminating the "best price" provision from the US Medicaid rebate formula for the top 100 single-source and innovator multiple-source drugs...

FUTURE PRODUCTS FROM GENETICS INSTITUTE

6 April 1992

Highlighting the most prominent products and product candidates in its commercial development pipeline, Genetics Institute acknowledges that significant progress has...

LOWER SALES/PROFIT FOR BAYER ITALY

6 April 1992

In line with the group's overall international performance, Bayer Italia reports lower sales and profits in 1991. The subsidiary of...